Catalog No.
DHD68908
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40
Concentration
1.32 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P25942
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
SGN-40, huS2C, CAS: 880486-59-9
Clone ID
Dacetuzumab
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial, PMID: 25651427
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma, PMID: 20133895
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma, PMID: 22775314
Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma, PMID: 21610152
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma, PMID: 19636010
Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells, PMID: 21394099
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors, PMID: 24919462
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia, PMID: 20038235
Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies, PMID: 19513947
Network meta-analysis of targeted therapies for diffuse large B cell lymphoma, PMID: 33308179
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4), PMID: 29572070
Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma, PMID: 32850331
Emerging antibodies for the treatment of multiple myeloma, PMID: 27195659
Emerging immune targets for the treatment of multiple myeloma, PMID: 29421983
Immunotherapy of cancer in 2012, PMID: 22576456
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials, PMID: 24555495
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development, PMID: 31544840
Humoral theory of transplantation: some hot topics, PMID: 23396319
Gateways to clinical trials, PMID: 19357798
Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art, PMID: 25249370
Gateways to clinical trials, PMID: 20140276
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma, PMID: 20425465
Updating targets for natural killer/T-cell lymphoma immunotherapy, PMID: 33628584
[Therapeutic monoclonal antibodies against multiple myeloma], PMID: 25626316
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma, PMID: 21411738
Statistical techniques to construct assays for identifying likely responders to a treatment under evaluation from cell line genomic data, PMID: 20979617
For research use only. Not for human or drug use.
